Since its discovery, leptin has been considered an attractive therapeutic target for the treatment of obesity and type 2 diabetes, due to its potency for the endocrine control of energy balance (Friedman, 2019). Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.